A study suggests that antibiotic use within one month of immune checkpoint inhibitor treatment may undermine survival in ...

In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 and ASPEN trials.

A study demonstrates that radiologic imaging significantly alters management strategies in nearly half of high-risk cutaneous ...

Just over a month after laying off staff to focus on its lead cancer candidate, ALX Oncology announced that the asset ...

ALX Oncology (ALXO) announced topline data from its Phase 2 ASPEN-03 and ASPEN-04 clinical trials. The company’s investigational CD47-blocker ...

Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment landscape for head and neck and lung cancer, and implications for specific drug ...

Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck ...

Home > Pressemitteilung: State of Mecklenburg-Vorpommern funds ...

Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates ...

The tumor microenvironment (TME) is a complex and dynamic network consisting of tumor cells, immune cells, stromal cells, ...

EQS-News: Pentixapharm Holding AG / Key word (s): Conference/Scientific publication Pentixapharm to Present First-in-Class Glycan-Dependent CD24 Antibody GT-008 for Solid Tumors at AACR 2025 ...